- Home
- TMCI vs CRVS Comparison
TMCI vs CRVS Comparison
Compare TMCI & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TMCI
- CRVS
- Stock Information
- Founded
- TMCI 2014
- CRVS 2014
- Country
- TMCI United States
- CRVS United States
- Employees
- TMCI N/A
- CRVS N/A
- Industry
- TMCI Biotechnology: Electromedical & Electrotherapeutic Apparatus
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- TMCI Health Care
- CRVS Health Care
- Exchange
- TMCI Nasdaq
- CRVS Nasdaq
- Market Cap
- TMCI 464.4M
- CRVS 516.0M
- IPO Year
- TMCI 2021
- CRVS 2016
- Fundamental
- Price
- TMCI $8.71
- CRVS $5.01
- Analyst Decision
- TMCI Hold
- CRVS Strong Buy
- Analyst Count
- TMCI 8
- CRVS 5
- Target Price
- TMCI $8.84
- CRVS $12.38
- AVG Volume (30 Days)
- TMCI 291.6K
- CRVS 1.6M
- Earning Date
- TMCI 02-27-2025
- CRVS 11-12-2024
- Dividend Yield
- TMCI N/A
- CRVS N/A
- EPS Growth
- TMCI N/A
- CRVS N/A
- EPS
- TMCI N/A
- CRVS N/A
- Revenue
- TMCI $202,861,000.00
- CRVS N/A
- Revenue This Year
- TMCI $13.18
- CRVS N/A
- Revenue Next Year
- TMCI $8.61
- CRVS N/A
- P/E Ratio
- TMCI N/A
- CRVS N/A
- Revenue Growth
- TMCI 16.14
- CRVS N/A
- 52 Week Low
- TMCI $3.92
- CRVS $1.30
- 52 Week High
- TMCI $15.98
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- TMCI 63.78
- CRVS 37.72
- Support Level
- TMCI $8.16
- CRVS $4.60
- Resistance Level
- TMCI $8.64
- CRVS $6.47
- Average True Range (ATR)
- TMCI 0.48
- CRVS 0.39
- MACD
- TMCI 0.12
- CRVS 0.03
- Stochastic Oscillator
- TMCI 93.09
- CRVS 21.93
About TMCI Treace Medical Concepts Inc.
Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The Company operates and manages its business as one segment, which is the business of designing, manufacturing, and marketing medical devices for physicians, surgeons, ambulatory surgery centers, and hospitals.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).